Randomized, Double-Blind, Placebo-Controlled, Multi-Centre, Multi-National Study to Evaluate the Efficacy and Safety of Oral BAY63-2521 (1 mg, 1.5 mg, 2 mg, or 2.5 mg Tid) in Patients With Symptomatic Pulmonary Arterial Hypertension (PAH)

Trial Profile

Randomized, Double-Blind, Placebo-Controlled, Multi-Centre, Multi-National Study to Evaluate the Efficacy and Safety of Oral BAY63-2521 (1 mg, 1.5 mg, 2 mg, or 2.5 mg Tid) in Patients With Symptomatic Pulmonary Arterial Hypertension (PAH)

Completed
Phase of Trial: Phase III

Latest Information Update: 26 Jan 2017

At a glance

  • Drugs Riociguat (Primary)
  • Indications Pulmonary arterial hypertension
  • Focus Registrational; Therapeutic Use
  • Acronyms PATENT-1
  • Sponsors Bayer
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 26 Jan 2017 According to a Bayer media release, data from this trial will be presented at the 11th annual World Congress of the Pulmonary Vascular Research Institute (PVRI).
    • 24 Dec 2016 Results assessing hemodynamic parameters in treatment-naive and pre-treated patients of phase III PATENT-1 study, published in the Journal of Heart and Lung Transplantation.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top